Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE2A | O00408 | 4/20 | 0.47 |
| ▸ | IDO1 | P14902 | 1/20 | 0.47 |
| ▸ | TDO2 | P48775 | 1/20 | 0.47 |
| ▸ | CES2 | O00748 | 5/20 | 0.42 |
| ▸ | CES1 | P23141 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.41 |
| ▸ | AKR1C2 | P52895 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | APP | P05067 | 1/20 | 0.38 |
| ▸ | PPARG | P37231 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6400526 | 1.00 | PDE2A (0.47) | PDE2AIDO1TDO2CES2CES1 | |
| SCHEMBL6400520 | 1.00 | PDE2A (0.47) | PDE2AIDO1TDO2CES2CES1 | |
| SCHEMBL8974847 | 0.86 | PDE2A (0.60) | PDE2ACES2CES1AKR1C3AKR1C2 | |
| SCHEMBL8974843 | 0.86 | PDE2A (0.60) | PDE2ACES2CES1AKR1C3AKR1C2 | |
| SCHEMBL6679457 | 0.83 | CES2 (0.51) | PDE2ACES2CES1MEN1KMT2A | |
| SCHEMBL6679460 | 0.83 | CES2 (0.51) | PDE2ACES2CES1MEN1KMT2A | |
| SCHEMBL6701810 | 0.83 | CES2 (0.51) | PDE2ACES2CES1MEN1KMT2A | |
| SCHEMBL16829661 | 0.81 | PDE2A (0.50) | PDE2ACES2CES1MEN1KMT2A | |
| SCHEMBL12388640 | 0.80 | PDE2A (0.55) | PDE2AIDO1TDO2CES2CES1 | |
| SCHEMBL6681467 | 0.79 | CES2 (0.51) | PDE2ACES2CES1KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6921758-B2 | Amino acid derivatives | ASTRAZENECA AB (SE) | 2005-07-26 | — | — | US | disclosed |
| US-20040087647-A1 | NEW AMINO ACID DERIVATIVES | ASTRAZENECA AB | 2004-05-06 | — | — | US | disclosed |
| US-6617320-B2 | Protease inhibitor; anticoagulants | ASTRAZENECA AB (SE) | 2003-09-09 | — | — | US | disclosed |
| EP-0836615-B1 | NEW THROMBIN INHIBITORS, THEIR PREPARATION AND USE | ASTRAZENECA AB (SE) | 2003-04-23 | — | — | EP | disclosed |
| US-20020042396-A1 | Amino acid derivatives | ASTRA AB | 2002-04-11 | — | — | US | disclosed |
| US-6051568-A | Thrombin inhibitors, their preparation and use | ASTRA AKTIEBOLAG (SE) | 2000-04-18 | — | — | US | disclosed |
| EP-0836615-A1 | NEW THROMBIN INHIBITORS, THEIR PREPARATION AND USE | Astra Aktiebolag (SE) | 1998-04-22 | — | — | EP | disclosed |
| WO-1997002284-A1 | NEW THROMBIN INHIBITORS, THEIR PREPARATION AND USE | ASTRA AKTIEBOLAG (SE) | 1997-01-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020042396-A1 | Amino acid derivatives | F2, SERPINC1, ARGLU1 | PDE2A 4348/4885IDO1 1144/4885TDO2 540/4885 |
| US-20040087647-A1 | NEW AMINO ACID DERIVATIVES | F2, ANPEP, PEPD | PDE2A 3358/4885IDO1 1036/4885TDO2 740/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.